▶ 調査レポート

医薬品有効成分(API)の世界市場:ビジネスモード別(キャプティブ(自社製)API、マーチャント型API)、合成タイプ別(合成、バイオテクノロジー)、顧客ベース別、用途別、地域別分析

• 英文タイトル:Global Active Pharmaceuticals Ingredients Market - Segmented by Business mode, Synthesis Type, Customer Base, Therapeutic Area, And Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。医薬品有効成分(API)の世界市場:ビジネスモード別(キャプティブ(自社製)API、マーチャント型API)、合成タイプ別(合成、バイオテクノロジー)、顧客ベース別、用途別、地域別分析 / Global Active Pharmaceuticals Ingredients Market - Segmented by Business mode, Synthesis Type, Customer Base, Therapeutic Area, And Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08012資料のイメージです。• レポートコード:B-MOR-08012
• 出版社/出版日:Mordor Intelligence / 2018年7月1日
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥629,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥666,000 (USD4,500)▷ お問い合わせ
  Corporate User¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、医薬品有効成分(API)の世界市場について調べ、医薬品有効成分(API)の世界規模、市場動向、市場環境、ビジネスモード別(キャプティブ(自社製)API、マーチャント型API)分析、合成タイプ別(合成、バイオテクノロジー)分析、顧客ベース別分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・医薬品有効成分(API)の世界市場インサイト
・医薬品有効成分(API)の世界市場環境
・医薬品有効成分(API)の世界市場動向
・医薬品有効成分(API)の世界市場規模
・医薬品有効成分(API)の世界市場規模:ビジネスモード別(キャプティブ(自社製)API、マーチャント型API)
・医薬品有効成分(API)の世界市場規模:合成タイプ別(合成、バイオテクノロジー)
・医薬品有効成分(API)の世界市場規模:顧客ベース別
・医薬品有効成分(API)の世界市場規模:用途別
・医薬品有効成分(API)の世界市場:地域別市場規模・分析
・医薬品有効成分(API)の北米市場規模・予測
・医薬品有効成分(API)のアメリカ市場規模・予測
・医薬品有効成分(API)のヨーロッパ市場規模・予測
・医薬品有効成分(API)のアジア市場規模・予測
・医薬品有効成分(API)の日本市場規模・予測
・医薬品有効成分(API)の中国市場規模・予測
・医薬品有効成分(API)のインド市場規模・予測
・医薬品有効成分(API)の韓国市場規模・予測
・関連企業情報・競争状況

The global active pharmaceutical ingredients market is expected to register a CAGR of approximately 6.2% during the forecast period (2018 – 2023). Active pharmaceutical ingredients are any substance or combination of substances used in a finished pharmaceutical product with pharmacological activity. The expenditure on research & development, favorable government initiatives, and high technological advancements makes North America the dominant market in the forecast period.

Rising Demand for Generic Drugs

Generic drugs benefit from the patent expiration of innovative drug as it makes them readily available in the market. The demand to produce quality medicines at lower and affordable costs creates a scenario, where the needs for generic drugs increase. It has been estimated that generic drugs save approximately USD 3 billion every week in the United States. In 2013, unbranded generic drugs accounted for more than 80% of the prescription drugs being distributed, primarily due to their low price for patients, payers, and the healthcare system. Therefore, the rise in the demand for generic drugs is expected to be one of the major drivers for the API market.
Other factors playing a vital role for the growth of this market include the rise in the geriatric population with an increase in chronic and lifestyles related disorders, technological advancements in the process of API manufacture, and rising preference for targeted therapy approach in cancer treatment.

Stringent Regulatory Framework

One of the major factors acting as an obstacle is the stringent regulatory framework across several regions. Moreover, the differences in the regulatory requirements in each country have made this an extremely complex market in the recent times. With European Union, several other countries are adopting fierce regulatory requirements and enforcing API inspection system similar to the level of FDA. This is a step towards standardized regulatory framework globally. These factors restrict the growth of companies in many regions and hinder the growth of this market.
Furthermore, other factors such as large capital investment, production cost, as well as variable drug price control policies hamper the growth of this market.

Asia-Pacific Expected to Register a High Growth Rate

The Asia-Pacific is expected to register a high growth rate compared to other regions during the forecast period, owing to the factors such as increasing healthcare expenditures, growing aging population creating a huge patient pool, and rising economies in this region.

Key Developments in the Market

• February 2018: ACETO Corporation with Rising Pharmaceuticals launched Atenolol tablets, 25mg, 50mg, and 100mg for hypertension.
• February 2018: Novo Nordisk invested an additional USD 65 million into the plant established in Clayton, North Carolina for building a USD 2 billion API facility there.
• January 2018: Sterling Pharma Solutions expanded its presence in the Asia region with growth experienced in the Japanese API market.

Major players: ABBOTT LABORATORIES, BOEHRINGER INGELHEIM, BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, JOHNSON & JOHNSON, MERCK & CO., INC, NOVARTIS INTERNATIONAL AG, ROCHE HOLDING AG, SANOFI SA, AND TEVA PHARMACEUTICAL INDUSTRIES LTD, among others.

Reasons to Purchase this Report

• Current and future of global active pharmaceutical ingredients market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Analysis on the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Degree of Competition
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Huge Impact from Pharmaceutical Industry
6.1.2 Increasing Adoption of Biologicals and Biosimilars
6.1.3 Rising Prevalence of Cancer
6.2 Market Restraints
6.2.1 Drug Price Control Policies Across Various Countries
6.2.2 Fierce Competition Between the API Manufacturers
6.2.3 Stringent Regulations
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Business Mode
7.1.1 Captive Active Pharmaceutical Ingredients (API)
7.1.2 Merchant Active Pharmaceutical Ingredients (API)
7.2 By Type of Synthesis
7.2.1 Synthetic
7.2.2 Biotech
7.3 By Customer Base
7.3.1 Generic
7.3.2 Branded
7.4 By Application
7.4.1 Cardiology
7.4.2 Pulmonology
7.4.3 Oncology
7.4.4 Ophthalmology
7.4.5 Neurology
7.4.6 Orthopedics
7.5 By Geography
7.5.1 North America
7.5.1.1 United states
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 United kingdom
7.5.2.3 Germany
7.5.2.4 Spain
7.5.2.5 Italy
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 India
7.5.3.2 China
7.5.3.3 Japan
7.5.3.4 Australia
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Albemarle Corporation
9.2 Aurobindo pharma
9.3 Boehringer Ingelheim GmbH
9.4 Dr. Reddy’s Lab
9.5 Lupin
9.6 Mylan N.V
9.7 Novartis
9.8 Pfizer, Inc
9.9 Ranbaxy Laboratories
9.10 Teva Active Pharmaceutical Industries Limited
10. Future Market Outlook